PRoduction of an innOvative Millifluidic dEvice for TEsting of new prObiotics

The PROMETEO project aims to develop a millifluidic platform for studying probiotics in the gut microenvironment, enhancing drug development and clinical trial success rates.

Subsidie
€ 150.000
2023

Projectdetails

Introduction

Over the last decades, the gut intestinal microflora and other microbial communities present in our body raised a strong interest in the health research domain as it was discovered their possible relation to the pathophysiology of major organs and systems.

Role of Gut Microbiota

Gut epithelial cells, together with our resident microbiota, are involved in the modulation of the host immune system and represent the first line of adsorption of drugs and nutraceuticals.

Probiotics Research

In parallel to microbiota studies, a great effort has been devoted to assess the role of the “probiotics,” live microorganisms that, administered in adequate amounts, are able to confer a benefit to the host health. Probiotics are currently widely used in the prevention/treatment of many diseases.

Challenges in Probiotic Characterization

One critical point that is still an issue in the characterization of new potential probiotics is the difficulty in mimicking with high reliability the gut microenvironment condition using animal models or the current in vitro tools, which are poorly representative of the real in vivo situation.

Need for Alternative Research Tools

This gap motivates the need for the development of alternative research tools, such as fluidic devices, to study the mechanisms at play in the human gut microenvironment and contribute to the success rate of expensive, risky, and time-consuming pre-clinical and clinical trials.

Project Overview

In this frame, our PROMETEO project aims to perform the technical and commercial feasibility of an integrated probiotic/gut epithelium/immune system millifluidic platform, based on a patented organ-on-a-chip technological device, providing the basis for a new generation of innovative solutions for probiotics/drug development.

Consortium Collaboration

PROMETEO will be run by a consortium between Politecnico di Milano and AAT-Advanced Analytical Technologies, a forefront SME specialized in promoting innovation in the probiotic sector, thus combining a solid technological expertise and an in-depth knowledge of the market.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-10-2023
Einddatum31-3-2025
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • POLITECNICO DI MILANOpenvoerder
  • AAT-ADVANCED ANALYTICAL TECHNOLOGIES-SRL

Land(en)

Italy

Vergelijkbare projecten binnen European Research Council

ERC Proof of...

Microbiome-based diagnostics and therapeutics

This project aims to develop microbiome-based diagnostic and therapeutic products by leveraging multi-omics data to identify predictive bacterial strains for disease onset and progression.

€ 150.000
ERC Starting...

Proteome-wide Functional Interrogation and Modulation of Gut Microbiome Species

This project aims to identify and manipulate gut microbiome protein functions using high-throughput proteomics to develop targeted therapies for restoring microbial health.

€ 1.499.980
ERC Starting...

Microbial Synthetic in vivo Cell Therapy Systems

The MiStiC project aims to develop Clostridium leptum as a stable chassis for localized drug production and delivery, targeting colorectal cancer through engineered biosensors and natural product pathways.

€ 1.499.938
ERC Starting...

Resolving metabolic interactions between the gut microbiota and the host with multi-omics-based modelling

This project aims to systematically characterize gut bacteria interactions and their metabolic contributions to host health using experimental and computational methods, enabling targeted microbiota interventions.

€ 1.499.323
ERC Starting...

Microbial ecosystems biology in the human gut

This project aims to develop a comprehensive ecosystem model of child gut microbiota using multiomic data to predict and manipulate microbial responses for improved health interventions.

€ 1.485.413

Vergelijkbare projecten uit andere regelingen

EIC Pathfinder

INTELLIGENT ENCAPSULATION AND SCREENING PLATFORM FOR PRECISION DELIVERY OF PROBIOTICS TO IMPROVE GUT HEALTH

iNSIGHT aims to develop precision probiotics through innovative microencapsulation for targeted delivery, enhancing gut health and addressing related diseases using advanced technology and personalized treatment.

€ 3.194.343
EIC Pathfinder

Understanding the potential of modulating Host-Microbiome-Glycan interactions (“the triangle of sweetness”) to tackle non-communicable diseases

The project aims to identify novel glycosyltransferases and HMOs, analyze their gut interactions, and validate an HMO for inflammation relief, enhancing glycobiology research and therapeutic applications.

€ 3.920.718
Mkb-innovati...

AdDitive mAnufacturing Microfluidica – ADAM

PimBio B.V. ontwikkelt kosteneffectieve, klantspecifieke microfluïdische chips voor biotechnologie en gezondheidszorg om onderzoek te versnellen.

€ 20.000
Mkb-innovati...

Sensoriek en Vloeistofadditie Microbioreactoren

Dit project ontwikkelt nieuwe sensoriek en vloeistofadditiesystemen voor microbioreactors om de biofarmaceutische ontwikkeling van medicijnen te versnellen en kosten te verlagen.

€ 350.000
EIC Transition

IDEFIX Multiorgan toxicity and efficacy test platform

Cherry Biotech's IDEFIX project aims to revolutionize preclinical drug testing by developing a customizable organ-on-chip platform that mimics human multiorgan physiology, enhancing efficacy and toxicity predictions.

€ 2.496.073